Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

Laura Kennedy, MD, PhD, has joined Vanderbilt University Medical Center from the University of Washington School of Medicine/Fred Hutchinson Cancer Research Center in Seattle where she was acting instructor and research associate.

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Robert Ramirez, DO, a thoracic and neuroendocrine oncologist, has joined Vanderbilt-Ingram Cancer Center after practicing at Ochsner Medical Center and Louisiana State University (LSU) Health Science Center in New Orleans.

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.